Virpax Pharmaceuticals Inc Cash Flow Conversion Efficiency
Virpax Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Virpax Pharmaceuticals Inc (VRPX) has a cash flow conversion efficiency ratio of 3.142x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($-913.76K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Virpax Pharmaceuticals Inc (2018–2024)
Cash flow conversion efficiency of Virpax Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Virpax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VRPX stock price and chart for real-time trading data and today's change.
Virpax Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Virpax Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Virpax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virpax Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see VRPX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Abingdon Health Plc
LSE:ABDX
|
-0.204x |
|
PCI Biotech Holding ASA
OL:PCIB
|
-0.501x |
|
Sino-German United AG
F:SGU
|
N/A |
|
Portmeirion Group PLC
LSE:PMP
|
-0.015x |
|
HARVEST MINERALS LTD
F:7HM
|
N/A |
|
Baltic Bridge S.A.
WAR:WIS
|
N/A |
|
Digital 9 Infrastructure PLC
LSE:DGI9
|
-0.162x |
|
C3is Inc.
NASDAQ:CISS
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Virpax Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Virpax Pharmaceuticals Inc from 2018 to 2024. Review how financially flexible is Virpax Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-913.76 Million | $-16.71 Billion | 18.290x | +459.04% |
| 2023-12-31 | $1.93 Million | $-9.85 Million | -5.094x | -373.23% |
| 2022-12-31 | $16.58 Million | $-17.85 Million | -1.076x | -177.47% |
| 2021-12-31 | $37.48 Million | $-14.54 Million | -0.388x | -218.11% |
| 2020-12-31 | $-4.22 Million | $-1.38 Million | 0.328x | -20.71% |
| 2019-12-31 | $-2.73 Million | $-1.13 Million | 0.414x | -72.55% |
| 2018-12-31 | $-1.19 Million | $-1.80 Million | 1.509x | -- |
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more